6-K 1 a53878315.htm LEGEND BIOTECH CORPORATION 6-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
Date of Report: January 9, 2024
 
Commission File Number: 001-39307

 
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)



2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F  ☒            Form 40-F  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


Legend Biotech Updates Corporate Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

On January 9, 2024, Legend Biotech Corporation (“Legend Biotech” or the “Company”) will make its updated corporate presentation available on its website. The presentation is attached to this Form 6-K as Exhibit 99.1 and may be viewed on the Company’s website at https://investors.legendbiotech.com/events-and-presentations.
 

This report on Form 6-K (except information contained on, or that can be accessed through, our website), including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-272222, 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.


EXHIBIT INDEX

                                     

Exhibit
  Title
     
99.1   Corporate Presentation – January 2024


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
LEGEND BIOTECH CORPORATION
 
 
 
 
Date: January 9, 2024
 
By:
/s/ Ying Huang
 
 
Name:
Ying Huang, Ph.D.
 
 
Title:
Chief Executive Officer